ReviewViruses2024
Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment.
Review in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Mapping the monoclonal antibody landscape of human cytomegalovirus.Journal of virology · 2026Review
- Ocular Manifestations Associated with Hematologic Malignancies: Mechanisms, Diagnosis, and Management.Medical sciences (Basel, Switzerland) · 2026Review
- Cytomegalovirus Infection of the Anterior Segment: Corneal Endotheliitis and Secondary Glaucoma.Pathogens (Basel, Switzerland) · 2026Review
- Diabetes Mellitus is a Risk Factor for Developing CMV Retinitis in Solid Organ Transplant Recipients: A Case-control Study.Open forum infectious diseases · 2026Article
- From infection to infarction: cytomegalovirus retinitis complicated by retinal ischemia and vitreous hemorrhage in the setting of JAK inhibition - a case report.BMC ophthalmology · 2026Article
- Cytomegalovirus retinitis during upadacitinib monotherapy for rheumatoid arthritis: a case report.Journal of rheumatic diseases · 2026Article
- Neurological Infections in HIV: A Case-Based Review for Clinicians.Le infezioni in medicina · 2026Review
- Factors influencing the treatment duration and visual prognosis of cytomegalovirus retinitis after allogeneic hematopoietic stem cell transplantation.International journal of ophthalmology · 2026Article
- Clinical prognostic value of TTV and HCMV but not EBV for outcomes in hospitalized HIV-positive patients.Biosafety and health · 2025Article
- Congenital cytomegalovirus retinitis of prematurity: a case report and literature review.Frontiers in pediatrics · 2025Article
- A case series: cytomegalovirus retinitis following autologous hematopoietic cell transplantation: a call for early detection and aggressive management.Frontiers in medicine · 2025Article
- Advances in Controlled Release Formulations for Ocular Diseases: Improving Patient Compliance and Therapeutic Outcomes.Current drug metabolism · 2025Review
- Epidemiological spectrum of infectious uveitis in the Asia-Pacific.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cytomegalovirus (CMV) retinitis is the most common eye disease associated with CMV infection in immunocompromised individuals. The CMVR may initially be asymptomatic; however, relatively mild vitreous inflammation at the onset may be an important differential point from other diseases in HIV patients. Fundus photography, CD4 T-cell count, and telemedicine could be used to screen and monitor the high-risk population, particularly in resource-limited regions. Retinitis generally starts in the peripheral retina and advances toward the posterior pole, which could develop to the characteristic "pizza pie" appearance marked by central retinal necrosis and intraretinal hemorrhage. CMVR causes vision loss if left untreated, and early antiviral therapy significantly reduces the risk of vision loss. Alongside traditional antiviral treatments, immunotherapies including CMV-specific adoptive T-cell therapy and CMV immunoglobulin (CMVIG) are emerging as promising treatment options due to their favorable tolerability and reduced mortality. This review comprehensively examines CMV retinitis, encompassing the clinical features, differential diagnosis, laboratory tests, and updated treatment strategies to inform clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.